Aim: Doxorubicin (DOXO) is a highly effective and extensively prescribed anticancer antracycline drug, however, its use is limited by multidrug resistance and dose-dependent cumulative cardiotoxicity. Administration of DOXO with widely used antidepressan fluoxetine (FLU) is one of the treatment strategies for multidrug resistance. In this study, we aimed the investigation of FLU-DOXO combination on biochemical cardiotoxicity markers.

Material and Method: Balb-c mice divided 4 group and treated 6 weeks: (1) control (serum physiologic), (2) FLU (0.5 mg/kg/day), (3) DOXO (cumulative dose 12 mg/kg), (4) FLU (0.5 mg/kg/day) ve DOXO (cumulative dose 12 mg/kg).

Results: Regarding to our results, FLU-DOXO combination increased serum high sensitivity Troponin T (hsTnT) levels. While DOXO treatment increased serum aspartate aminotransferase (AST) and cardiac total oxidant capacity (TOS), serum alanine aminotransferase (ALT), lactate dehydrogenase (LDH) and creatine kinase-MB (CK-MB) levels were unchanged.

Conclusion: Administration of DOXO with FLU may cause early stage cardiotoxicity which is determined by hsTnT.